GlaxoSmithKline’s ViiV Healthcare To Purchase Experimental HIV Medicines From Bristol-Myers Squibb For Up To $1.46B
Bloomberg Business: Glaxo to Pay Bristol-Myers Up to $1.46 Billion for HIV Drugs
“GlaxoSmithKline Plc agreed to buy Bristol-Myers Squibb Co.’s portfolio of experimental HIV treatments for as much as $1.46 billion in two transactions, bolstering one of the U.K. drugmaker’s fastest-growing businesses…” (Serafino/Kitamura, 12/18).
Financial Times: GSK spends up to $1.5bn on HIV drugs in BMS deal
“…The U.K.-based drugmaker said its HIV unit, known as ViiV Healthcare, would buy a range of experimental therapies in late-stage development and a further package of early-stage assets in two separate transactions…” (Ward, 12/18).
Reuters: GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 million
“…The British company is reviving its position in HIV treatment as part of its strategy to return to earnings growth in 2016. It used to dominate the market but ViiV’s 2014 sales of 1.5 billion pounds ($2.3 billion) were less than a quarter of the HIV revenue generated by market leader Gilead Sciences…” (Young, 12/18).
Wall Street Journal: GlaxoSmithKline Buys Bristol-Myers Squibb’s HIV Assets
“…The deal does not include Bristol’s marketed HIV drugs, which include Reyataz, Evotaz, Sustiva, and Atripla. The companies said they expected the transactions to close in the first half of 2016” (Roland, 12/18).